1. Breast edema in breast cancer patients following breast-conserving surgery and radiotherapy: a systematic review

   • Hanne Verbelen
   • Nick Gebruers
   • Wiebren Tjalma

   Review 28 August 2014 Pages: 463 - 471

   

2. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer

   • Yassine Rechoum
   • Daniela Rovito
   • Suzanne A. W. Fuqua

   Preclinical Study 02 September 2014 Pages: 473 - 485

   

3. JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3

   • Liliang Li
   • Pan Gao
   • Jieqing Jiang

   Preclinical study 06 September 2014 Pages: 487 - 500

   

4. An improved syngeneic orthotopic murine model of human breast cancer progression

   • Omar M. Rashid
   • Masayuki Nagahashi
   • Kazuaki Takabe

   Preclinical study 09 September 2014 Pages: 501 - 512

   

5. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer

   • M. Tanioka
   • K. Sakai
   • K. Nishio

   Preclinical study 09 September 2014 Pages: 513 - 525

   

6. Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes

   • S. D. Soysal
   • S. Muenst
   • W. E. Gillanders

   Preclinical Study 12 September 2014 Pages: 527 - 537

   

7. Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells

   • Allison B. Haugrud
   • Yongxian Zhuang
   • W. Keith Miskimins

   Preclinical study 12 September 2014 Pages: 539 - 550

   

8. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China

   • Xinxin Zhu
   • Jianming Ying
   • Hongying Yang

   Preclinical Study 19 September 2014 Pages: 551 - 555

9. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel

   • C. Vulsteke
   • A. M. Pfeil
   • H. Wildiers

   Clinical trial 29 August 2014 Pages: 557 - 570

   

10. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer

    • Martin P. Nilsson
    • Linda Hartman
    • Niklas Loman

    Clinical trial Open access 04 September 2014 Pages: 571 - 578

    

11. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer

    • Gayle S. Jameson
    • Emanuel F. Petricoin
    • Nicholas J. Robert

    Clinical trial 11 September 2014 Pages: 579 - 588

    

12. Diagnostic accuracy of tactile imaging in selecting patients with palpable breast abnormalities: a prospective comparative study

    • Marios-Konstantinos Tasoulis
    • Konstantinos E. Zacharioudakis
    • Dimitri J. Hadjiminas

    Clinical trial 11 September 2014 Pages: 589 - 598

    

13. Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

    • Patrizia Vici
    • Laura Pizzuti
    • Teresa Gamucci

    Clinical trial Open access 19 September 2014 Pages: 599 - 607

    

14. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage

    • Lu Chen
    • Hannah M. Linden
    • Christopher I. Li

    Epidemiology 28 August 2014 Pages: 609 - 616

    

15. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?

    • Wilson Sheridan
    • Tyldesley Scott
    • Chia Stephen

    Epidemiology 11 September 2014 Pages: 617 - 629

    

16. Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine

    • George Dranitsaris
    • Mario E. Lacouture

    Epidemiology Open access 13 September 2014 Pages: 631 - 638

    

17. Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses’ Health Study

    • Megan A. Healey
    • Rong Hu
    • Aditi Hazra

    Epidemiology 16 September 2014 Pages: 639 - 651

    

18. Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1

    • Sagar Ghosh
    • Fei Gu
    • Rong Li

    Epidemiology 19 September 2014 Pages: 653 - 659

    

19. Neighborhood socioeconomic deprivation, tumor subtypes, and causes of death after non-metastatic invasive breast cancer diagnosis: a multilevel competing-risk analysis

    • Min Lian
    • Maria Pérez
    • Donna B. Jeffe

    Epidemiology 19 September 2014 Pages: 661 - 670

    

20. A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts

    • J. Mathew
    • S. Lee
    • K. L. Cheung

    Brief Report 23 August 2014 Pages: 671 - 674

    

21. Mesothelin expression is associated with poor outcomes in breast cancer

    • Yun R. Li
    • Rena R. Xian
    • Julia Tchou

    Brief Report 06 September 2014 Pages: 675 - 684

    

22. MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis

    • Filippo Santoro
    • Franca Podo
    • Francesco Sardanelli

    Letter to the Editor 02 September 2014 Pages: 685 - 687

23. Response to Santoro et al

    • D. Gareth Evans

    Rebuttal Letter 05 September 2014 Pages: 689 - 689

24. Erratum to: MRI breast screening in high-risk women: cancer detection and survival analysis

    • D. Gareth Evans
    • Nisha Kesavan
    • Stephen W. Duffy

    Erratum 09 September 2014 Pages: 691 - 691